Pulmatrix (PULM) Competitors

$1.26 -0.01 (-0.39%)

As of 10:40 AM Eastern

PULM vs. PASG, COCP, LGVN, TRAW, and NCEL

Should you buy Pulmatrix stock or one of its competitors? MarketBeat compares Pulmatrix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulmatrix include Passage Bio (PASG), Cocrystal Pharma (COCP), Longeveron (LGVN), Traws Pharma (TRAW), and NLS Pharmaceutics (NCEL). These companies are all part of the "pharmaceutical products" industry.

How does Pulmatrix compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Pulmatrix has higher revenue and earnings than Passage Bio. Pulmatrix is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$14.48	N/A
Pulmatrix	$7.81M	0.59	-$5.16M	-$1.41	N/A

Passage Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Pulmatrix's return on equity of -96.97% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Pulmatrix	N/A	-96.97%	-88.53%

In the previous week, Passage Bio and Passage Bio both had 4 articles in the media. Passage Bio's average media sentiment score of 0.97 beat Pulmatrix's score of 0.44 indicating that Passage Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulmatrix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Passage Bio presently has a consensus price target of $13.25, indicating a potential upside of 152.38%. Given Passage Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Passage Bio is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Passage Bio beats Pulmatrix on 8 of the 13 factors compared between the two stocks.

How does Pulmatrix compare to Cocrystal Pharma?

Pulmatrix (NASDAQ:PULM) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Pulmatrix has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.59	-$5.16M	-$1.41	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.79	N/A

Pulmatrix has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Pulmatrix's return on equity of -96.97% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-96.97%	-88.53%
Cocrystal Pharma	N/A	-132.61%	-89.83%

In the previous week, Cocrystal Pharma had 1 more articles in the media than Pulmatrix. MarketBeat recorded 5 mentions for Cocrystal Pharma and 4 mentions for Pulmatrix. Cocrystal Pharma's average media sentiment score of 0.96 beat Pulmatrix's score of 0.44 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmatrix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cocrystal Pharma has a consensus price target of $6.00, indicating a potential upside of 385.83%. Given Cocrystal Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Cocrystal Pharma is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 0.6% of Pulmatrix shares are held by company insiders. Comparatively, 28.1% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Pulmatrix and Cocrystal Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Pulmatrix compare to Longeveron?

Longeveron (NASDAQ:LGVN) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Longeveron currently has a consensus price target of $5.50, indicating a potential upside of 699.42%. Given Longeveron's stronger consensus rating and higher possible upside, equities analysts plainly believe Longeveron is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Longeveron has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

10.0% of Longeveron shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 11.2% of Longeveron shares are held by company insiders. Comparatively, 0.6% of Pulmatrix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pulmatrix has higher revenue and earnings than Longeveron. Pulmatrix is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.22M	13.16	-$22.70M	-$1.13	N/A
Pulmatrix	$7.81M	0.59	-$5.16M	-$1.41	N/A

Pulmatrix has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Pulmatrix's return on equity of -96.97% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-237.79%	-158.07%
Pulmatrix	N/A	-96.97%	-88.53%

In the previous week, Longeveron had 12 more articles in the media than Pulmatrix. MarketBeat recorded 16 mentions for Longeveron and 4 mentions for Pulmatrix. Pulmatrix's average media sentiment score of 0.44 beat Longeveron's score of 0.15 indicating that Pulmatrix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	2 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmatrix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Longeveron and Pulmatrix tied by winning 8 of the 16 factors compared between the two stocks.

How does Pulmatrix compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Traws Pharma has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market.

Traws Pharma currently has a consensus price target of $8.00, indicating a potential upside of 393.83%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Traws Pharma is more favorable than Pulmatrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Traws Pharma has higher earnings, but lower revenue than Pulmatrix. Pulmatrix is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	5.90	$9.17M	$0.93	1.74
Pulmatrix	$7.81M	0.59	-$5.16M	-$1.41	N/A

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 14.0% of Traws Pharma shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Traws Pharma had 3 more articles in the media than Pulmatrix. MarketBeat recorded 7 mentions for Traws Pharma and 4 mentions for Pulmatrix. Traws Pharma's average media sentiment score of 0.70 beat Pulmatrix's score of 0.44 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Traws Pharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulmatrix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Traws Pharma's return on equity of 112.18% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	112.18%	35.31%
Pulmatrix	N/A	-96.97%	-88.53%

Summary

Traws Pharma beats Pulmatrix on 13 of the 16 factors compared between the two stocks.

How does Pulmatrix compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Pulmatrix has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Pulmatrix	$7.81M	0.59	-$5.16M	-$1.41	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NLS Pharmaceutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market.

In the previous week, Pulmatrix had 3 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 4 mentions for Pulmatrix and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.89 beat Pulmatrix's score of 0.44 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Very Positive
Pulmatrix	Neutral

NLS Pharmaceutics' return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Pulmatrix	N/A	-96.97%	-88.53%

11.8% of Pulmatrix shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 0.6% of Pulmatrix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Pulmatrix beats NLS Pharmaceutics on 5 of the 9 factors compared between the two stocks.

Get Pulmatrix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PULM vs. The Competition

Export

Metric	Pulmatrix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.62M	$3.36B	$6.27B	$12.28B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.90	18.44	20.47	25.38
Price / Sales	0.59	285.78	540.59	73.72
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	0.52	6.77	9.82	6.85
Net Income	-$5.16M	$24.11M	$3.55B	$333.62M
7 Day Performance	-2.47%	3.83%	0.67%	-0.07%
1 Month Performance	1.20%	-2.51%	-0.40%	1.79%
1 Year Performance	-80.60%	70.67%	37.38%	32.91%

Pulmatrix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PULM Pulmatrix	0.7069 of 5 stars	$1.27 -0.4%	N/A	-79.2%	$4.62M	$7.81M	N/A	20	News Coverage Earnings Report Short Interest Increase
PASG Passage Bio	3.2811 of 5 stars	$5.52 +9.7%	$13.25 +140.0%	+0.5%	$17.72M	N/A	N/A	130	Earnings Report Short Interest Increase Gap Down
COCP Cocrystal Pharma	2.7584 of 5 stars	$1.28 -2.3%	$6.00 +368.8%	-13.7%	$17.65M	N/A	N/A	10	News Coverage Positive News Earnings Report Upcoming Earnings Short Interest Decrease
LGVN Longeveron	2.8891 of 5 stars	$0.76 +0.7%	$5.50 +628.5%	-48.0%	$17.57M	$1.20M	N/A	20	News Coverage Earnings Report
TRAW Traws Pharma	4.1355 of 5 stars	$1.72 +2.4%	$8.00 +365.1%	+31.5%	$17.48M	$2.79M	1.85	17	Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PULM) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmatrix (PULM) Competitors

PULM vs. PASG, COCP, LGVN, TRAW, and NCEL

How does Pulmatrix compare to Passage Bio?

Summary

How does Pulmatrix compare to Cocrystal Pharma?

Summary

How does Pulmatrix compare to Longeveron?

Summary

How does Pulmatrix compare to Traws Pharma?

Summary

How does Pulmatrix compare to NLS Pharmaceutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PULM vs. The Competition

Pulmatrix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmatrix (PULM) Competitors

PULM vs. PASG, COCP, LGVN, TRAW, and NCEL

How does Pulmatrix compare to Passage Bio?

Which has stronger earnings and valuation, PASG or PULM?

Which has more volatility and risk, PASG or PULM?

Is PASG or PULM more profitable?

Does the media favor PASG or PULM?

Do analysts recommend PASG or PULM?

Do insiders & institutionals believe in PASG or PULM?

Summary

How does Pulmatrix compare to Cocrystal Pharma?

Which has stronger earnings and valuation, PULM or COCP?

Which has more volatility and risk, PULM or COCP?

Is PULM or COCP more profitable?

Does the media refer more to PULM or COCP?

Do analysts rate PULM or COCP?

Do institutionals & insiders believe in PULM or COCP?

Summary

How does Pulmatrix compare to Longeveron?

Do analysts recommend LGVN or PULM?

Which has more risk and volatility, LGVN or PULM?

Do insiders and institutionals believe in LGVN or PULM?

Which has higher valuation & earnings, LGVN or PULM?

Is LGVN or PULM more profitable?

Does the media prefer LGVN or PULM?

Summary

How does Pulmatrix compare to Traws Pharma?

Which has more volatility & risk, TRAW or PULM?

Do analysts recommend TRAW or PULM?

Which has stronger valuation and earnings, TRAW or PULM?

Do institutionals and insiders believe in TRAW or PULM?

Does the media prefer TRAW or PULM?

Is TRAW or PULM more profitable?

Summary

How does Pulmatrix compare to NLS Pharmaceutics?

Which has stronger valuation and earnings, NCEL or PULM?

Do analysts recommend NCEL or PULM?

Which has more volatility & risk, NCEL or PULM?

Does the media prefer NCEL or PULM?

Is NCEL or PULM more profitable?

Do institutionals and insiders believe in NCEL or PULM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PULM vs. The Competition

Pulmatrix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools